melanoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
melanoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
(1) The underlying melanoma-driving mutations may give rise to specific dermoscopic growth patterns, (2) BRAF/NRAS mutations in early melanomas may not be as common as previously thought, and (3) patients may be predisposed to developing specific driving mutations giving rise to melanomas or nevi of similar growth patterns.
|
24695820 |
2014 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
23 and 26 patients were concluded to have a NRAS-mutated or a BRAF-mutated melanoma respectively.
|
26204954 |
2015 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
|
21107323 |
2010 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Melanomas without chronic sun-induced damage (Non-CSD) were more likely (P<0.01) to show BRAF mutations while NRAS mutation frequency was unbiased between melanoma subtypes.
|
21788131 |
2012 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Melanoma is a heterogenous disease and can be subclassified based on distinct clinical characteristics, histopathological features and mutation patterns within NRAS and BRAF genes.
|
22621697 |
2013 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Melanomas with NF1 mutations typically occur on chronically sun-exposed skin or in older individuals, show a high mutation burden, and are wild-type for BRAF and NRAS.
|
28067895 |
2017 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Melanoma onset and progression are associated with a high variety of activating mutations in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) genes, but also c-KIT and PTEN.
|
31446019 |
2019 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
|
17119447 |
2006 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
|
17119447 |
2006 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutations occur in approximately 20% of human melanomas, whereas HRAS and KRAS mutations are rare in this disease.
|
17297468 |
2007 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutations have long been known to be present in a subset of melanomas and represent an elusive subgroup for targeted therapies.
|
21670085 |
2011 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
NRAS and BRAF mutation and protein expression have been studied in other melanoma subtypes.
|
21750866 |
2011 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
NRAS mutational status is a new candidate biomarkers for selecting patients with melanoma for HD IL-2 treatment.
|
22130161 |
2012 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
NRAS and CKIT mutant melanoma represent the next oncogene defined melanoma subsets for which initial targeted therapy approaches are being explored, with early evidence suggesting progress with MEK and CKIT inhibitors, respectively.
|
22661223 |
2012 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations.
|
23096702 |
2013 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutations were most frequently detected in acral melanomas (9.3 %), followed by melanomas without chronic sun-induced damage (7.0 %) and mucosal melanomas (4.8 %), and were not detected in melanomas with chronic sun-induced damage.
|
23739925 |
2014 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
|
24802725 |
2014 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
NRAS and BRAF mutational status has become mandatory to treat patients with metastatic melanomas.
|
26297254 |
2015 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutations were rare in VVMs compared with cutaneous (25.9%; P = .009) and acral (40.6%; P = .002) melanoma subtypes.
|
28026870 |
2017 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS-mutant tumors tended to behave more aggressively particularly in early stages of the disease in this high-risk melanoma population.
|
28797232 |
2017 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutated melanoma were mainly observed in chronic sun-damaged areas and had a negative prognostic value, with shorter time to progression and a high incidence of central nervous system involvement.
|
29187493 |
2017 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A 80 year-old man with stage IV BRAF-wild type and NRAS exon 2-mutated melanoma was treated first line by nivolumab 3mg/kg every 2 weeks.
|
28438383 |
2017 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A B-RAF or N-RAS mutation was found in 8 of 23 (35%) spitzoid lesions suspected for melanoma.
|
16096402 |
2005 |